Sarcoma Immunotherapy: Past Approaches and Future Directions

Figure 1

Preventing tumorigenesis in sarcoma. The adaptive immune response initiates with presentation of antigens by DC. DC migrates to the lymph node. Antigens are presented to CD4⁺ and CD8⁺ T cells through MHC class I and II, respectively, and costimulatory molecules such as B7 bind to CD28 leading to activation of the lymphocytes. Once stimulated, these lymphocytes are now effector cells with the ability to migrate to the tissue and initiate an immune response against the developing sarcoma (abbreviations: CTL, cytotoxic T lymphocyte; DC, dendritic cell; TH, T helper lymphocyte). Reference: adapted from [25].